Cells were managed in 10% fetal bovine serum, 1 g/ml blasticidin and minimum essential medium at 37C in a humidified 5% CO2atmosphere

Cells were managed in 10% fetal bovine serum, 1 g/ml blasticidin and minimum essential medium at 37C in a humidified 5% CO2atmosphere. For SILAC experiments, cells were produced in the presence of regular Arg, Arg that contain six13C (Arg6) or Arg containing six13C and four15N (Arg10) for at least 10 passages to labeled proteins to ~99% with Arg, Arg6 or Arg10. == Receptor purification == The following buffers were used for receptor purification: Buffer A, 20mM Tris, pH 7. 4, 1% n-Dodecyl–D-maltoside (DDM), 0. 1 M NaCl, phosphatase inhibitors including 20 mM Na4pyrophosphate, 20 mM Na2glycerophosphate, 20 mM NaF, 1mM orthovanadate, 10 mM imidazole and protease inhibitors tablet, pH adjusted to 8. 0; Buffer B, 20mM Tris, pH 7. 4, 0. 1% DDM, 0. 5M NaCl, phosphatase inhibitors mix in buffer A at 1/10 from the original concentrations, 10 mM imidazole; Buffer C, Buffer B + 0. Fexaramine 25M imidazole; Buffer D, 20mM Tris, pH 7. 4, 0. 05% DDM; Buffer E, Buffer D + 0. 5M NaCl; Buffer F, Buffer D + 0. 15M NaCl + 100g/ml FLAG peptide. Twenty 10-cm dishes of cells at ~70% confluence (1. 4 108cells) were cleaned, incubated with serum-free medium for 2 h after which treated with or with out 10 M U50, 488H for 30 min at 37C and medium aspirated. KOPR promoted single phosphorylation primarily at T363 and S369 with U/E percentage of 2. five and 2, respectively. Both induced double phosphorylation at T363+S369 and T357+S369 with ratios of U/E=3. several and several. 4, respectively. Only U50, 488H induced triple phosphorylation at S356+T357+S369. An unphosphorylated KOPR(354372) fragment containing all the Fexaramine phosphorylation sites was detected with a percentage of C/E/U =1/0. 7/0. 4, indicating that ~60% and ~30% from the mKOPR are phosphorylated following U50, 488H and etorphine, respectively. Thus, KOPR internalization requires receptor phosphorylation above a certain threshold and higher-order KOPR phosphorylation may be disproportionally important. Keywords: kappa opioid receptor, phosphorylation sites, endocytosis threshold, phospho-kappa opioid receptor specific antibody, SILAC == (a) Launch == Kappa opioid receptor (KOPR) is one of the three opioid receptors (, and ), which mediate the effects of opioid drugs and endogenous peptides. KOPR belongs to the rhodopsin sub-family of the seven transmembrane receptor (7TMR) family members. Activation from the KOPRin vivoproduces many effects including analgesia (1), dysphoria/aversion (2, 3), water diuresis (4), and antipruritic effects (5). U50, 488H is the prototypic selective nonpeptide KOPR full agonist (1). It has been demonstrated that signal transduction of 7TMRs entails both G proteins- and -arrestin-mediated pathways [reviewed in (6)]. The KOPR acts through Gi/o protein to inhibit adenylyl cyclase and N-type and L-type Ca++channels and activate inwardly rectifying K+channels and ERK1/2 [reviewed in (7)]. In addition , activated KOPR undergoes GRK-mediated phosphorylation and -arrestin-dependent desensitization, internalization and down-regulation [reviewed in (8)]. Moreover, activation of the KOPR enhances ERK1/2 and p38 MAP kinase phosphorylation in -arrestin-dependent manner (9, 10). Therefore , agonist-promoted phosphorylation of KOPR is actually a key event in signaling, trafficking and regulation of the receptor. Chavkin and colleagues have suggested that KOPR-induced analgesia is usually mediated by the G protein pathway (11), whereas aversion is created by the -arrestin-mediated p38 MAP kinase phosphorylation (9). However , recently White et al. (12) reported that the G protein-biased KOPR agonist RB64 produced analgesia and conditioned place aversion (CPA). Because of the pivotal role of KOPR phosphorylation in signaling, it is important to understand molecular details of this event. Previously MacLaughlin et al. (13) demonstrated that S369A mutation in the rat KOPR, which has the same C-terminal domain name sequence because the mouse KOPR, inhibited agonist-promoted internalization and desensitization. However , S369 may not be the only phosphorylation site. In this research, we determined the sites of U50, 488H-induced phosphorylation in the mouse KOPR by high performance liquid chromatography – tandem mass spectrometry (LC-MS/MS) analysis of Glu-C treated purified KOPR. We then generated antiserum against phosphopeptides and purified antibodies were proven to be specific to get phospho-KOPR in immunoblotting. We found that U50, 488H promoted strong KOPR internalization, whereas etorphine caused low or no internalization, even though both were full agonists in enhancing [35S]GTPS binding. We then analyzed whether Fexaramine the two agonists differentially phosphorylated KOPR. Two techniques were utilized: immunoblotting with phospho-specific KOPR antibodies and stable isotope-labeled amino acids in cells (SILAC) followed by LC-MS/MS. SILAC uses stable isotope-labeled amino acids to differentially labeled proteins in cultured cells and utilizes the high resolution of mass spectrometry to quantify the differences in the great quantity of the same peptide, which is differentially labeled with stable isotopes, following diverse treatments (14, 15). == (b) Experimental Procedures == == Components == Mouse neuro2A (N2A) cell was purchased coming from ATCC. U50, 488H, etorphine and nor-binaltorphimine (nor-BNI) were provided by the National Institute on Drug Abuse (Bethesda, MD). Rabbit anti-FLAG antibody (F7425) and mouse monoclonal anti-FLAG M2 affinity agarose were purchased coming from Sigma-Aldrich (St. Louis, MO). The rabbit anti-mKOPR (PA847) and anti-phophopeptides antisera were custom-developed by Covance Co. (Denver, PA) and purified in our personal laboratory. Almost all peptides were custom-synthesized by EZBiolab Inc. (Carmel, IN). The horseradish peroxidase (HRP) conjugated goat anti-rabbit or anti-mouse IgG antibodies were purchased coming from Jackson ImmunoResearch (West Grove, PA). The minimal essential medium (MEM), blasticidin, Lipofectamine 2000, pcDNA3. 1, pcDNA6/Myc-6His plasmids and the precast solution (412% Bis-Tris plus) were purchased coming from Invitrogen Thermo Fisher Medical (Carlsbad, CA). The fetal bovine serum AMLCR1 (FBS) was purchased coming from Atlanta Biochemicals (Flowery Branch, GA). The SulfoLink coupling resin column, chromatography columns, protease inhibitor tablet, 13C6L-Arginine, 13C615N4L-Arginine, MEM medium minus L-arginine and dialyzed fetal bovine serum and enhanced chemiluminescence (ECL) reagent Supersignal West Pico were purchased from Pierce Thermo Fisher Scientific (Rockford, IL). The lambda phosphatase was purchased from New England BioLabs (Ipswich, MA). The Ni-NTA Agarose was purchased coming from Qiagen GmbH (Hilden, Germany). Dodecyl–D-maltoside (DDM) was purchased Fexaramine from EMD Biosciences, Inc. (La Jolla, CA). All other chemicals were purchased coming from Sigma-Aldrich..